Collectively, these results suggest that effective anti-melanoma therapy might include strategies directed at blocking key molecular events such as proteasome activity, HDAC and Stat3; their targeting might be effectively associated with the inhibition of either hyper-activated pathways or anti-apoptotic molecules, in order to achieve better disease control. This evidence concerns the gene HDAC9 and melanoma.